Medical XpressSingle Dose of Fast-Acting Psychedelic Nasal Spray Shows Promise for Stubborn Depression

⚠️ Small Study / Early Comparative Evidence

Shorter psychedelic treatment sessions could address a logistical barrier, but recovery time and antidepressant efficacy require separate evaluation. Researchers randomized 193 adults with treatment-resistant depression across 38 sites to intranasal mebufotenin benzoate at 8 mg, 12 mg, or a 0.3 mg control dose. Higher doses showed symptom improvement and generally brief recovery periods. The supplied report describes benefits through eight weeks but omits detailed adverse-event findings and statistical uncertainty.

Clinical Considerations

• Participants had failed two to five antidepressant treatments during the current episode, defining a selected treatment-resistant population.
• At four weeks, 12 mg improved clinician-rated depression scores by approximately five points more than control; 8 mg reportedly performed similarly.
• Roughly one-third of higher-dose recipients achieved at least 50% symptom reduction; the report does not provide the corresponding control response rate.
• Discharge readiness within two hours occurred in 85% at 8 mg and 78% at 12 mg; readiness does not establish comprehensive safety.
• Distinctive psychedelic effects could compromise blinding despite the low-dose control; the supplied report does not describe blinding-success assessments.
• Eight-week follow-up cannot establish maintenance efficacy, repeat-dosing needs, or long-term safety; confidence intervals and adverse-event rates require primary-source review.

Practice Applications

• Interpret the findings as a clinical research signal, not evidence supporting routine substitution for established depression treatments.
• Recognize that brief psychedelic effects do not demonstrate that the psychedelic experience is unnecessary for antidepressant benefit.
• Review primary-trial safety, eligibility, concomitant-treatment, and monitoring details before drawing conclusions about patient suitability or service-delivery advantages.